Court temporarily bars Aarti Pharmalabs from selling Ruxolitinib drugs

Litigation LossEnforcement RaidRegulatory & Legal View source PDF Explain this filing

AARTIPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹830.00

prior close

₹836.60

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.3%+0.9% vs market

Pharmaceuticals peers, median of 152sector-0.6%+1.2% vs sector

On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

+0.2

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6-0.3+0.9-0.6+1.2

Next day

+0.6-0.1+0.7-0.1+0.7

+0.3+0.6-0.3+0.7-0.4

-0.4+0.1-0.4-0.1-0.2

-0.5-1.1+0.5-0.9+0.4

+0.8-0.1+0.9-0.7+1.5

+1.1-0.1+1.2-0.6+1.7

15d

+0.4+2.1-1.7-0.1+0.5

-8.2+0.3-8.5-2.4-5.8

-15.3-6.3-9.1-6.0-9.3

-12.0-4.7-7.3-6.3-5.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Delhi High Court temporarily barred Aarti Pharmalabs from making, stocking, exporting, selling or supplying Ruxolitinib products that could infringe Indian patent IN269841. A local inspection team also visited the company office and copied ledgers and stock records. The company says it cooperated, operations continued normally, and there is no financial impact.

Likely market impact

The order restricts one product line and creates possible legal and sales risk, but the company reports no current financial or operational impact.